Group 1 - The article discusses the performance and outlook of Travere Therapeutics, Inc. (NASDAQ: TVTX), highlighting its recent approval for the therapy Filspari (sparsentan) [1] - The author provides insights into the biotech, pharma, and healthcare industries, emphasizing the importance of understanding key trends and catalysts that drive valuations [1] - The investing group Haggerston BioHealth offers resources for both novice and experienced biotech investors, including product sales forecasts and market analysis [1] Group 2 - The article is authored by a biotech consultant with over five years of experience in the industry, who has prepared detailed reports on more than 1,000 companies [1] - The focus is on providing buy and sell ratings, as well as financial analyses such as discounted cash flow analysis [1]